Mar. 17, 2014, 9:10 AM
- GlaxoSmithKline (GSK) will hire doctors to educate their peers instead of paying external speakers.
- This is one of several initiatives the firm is implementing after paying a $3B fine to settle allegations that it illegally promoted Paxil and Wellbutrin and failed to report safely data on Avandia.
- The company will cease paying outside doctors for giving speeches and attending medical meetings by early 2016.
Mar. 11, 2014, 9:24 AM
- GlaxoSmithKline (GSK), Johnson & Johnson (JNJ) and TPI Enterprises want the government of Australia to let them grow poppies on the country's mainland, due to a shortage of opium for pain killers and amid soaring demand.
- Australia only allows poppy growing in Tasmania, which is responsible for around half of the world's supply of opiate-based pain relief. Recent drought and storms in Tasmania have meant that drug firms can't get enough crops.
Mar. 10, 2014, 10:00 AM
- The WSJ profiles "pharmaceutical scouts," who, like talent-spotters in baseball "trying to pick tomorrow's big-leaguers from farm teams," search outside their companies to find drug candidates that have the potential to become blockbusters.
- In 2011, for instance, Johnson & Johnson's (JNJ) Peter Lebowitz helped his company beat competitors such as Novartis (NVS) to buy the rights to a blood-cancer drug from Pharmacyclics (PCYC) called Imbruvica.
- The treatment was eventually approved in November for a rare lymphoma and for chronic lymphocytic leukemia in February. J.P. Morgan forecasts Imbruvica will generate $1.3B in revenue for J&J in 2017.
- Half of J&J's drug pipeline is from outside the company, up from 20% in 2002.
- Other related tickers: MRK, RHHBY, BMY, SNY, CELG, GSK
Mar. 10, 2014, 7:36 AM
- GlaxoSmithKline (GSK +0.8% in London) increases its stake in Indian unit GlaxoSmithKline Pharmaceuticals Ltd to 75% from 50.7% for 64B rupees ($1.05B).
- The subsidiary's shares will continue to trade publicly.
- GSK offered to pay 3,100 rupees/share as part of an open offer to investors between February 18 and March 5. The company flagged its intention to raise its holding in the subsidiary in December.
- GSK said the transaction "further increases our exposure to a strategically important market." The unit provides respiratory, cardiovascular and cancer drugs, antibiotics, and vaccines.
- Just over a year ago, GSK paid $901M to raise its holdings in another Indian unit, GlaxoSmithKline Consumer Healthcare, to 72.5% from 43.2%. (PR)
Mar. 4, 2014, 12:00 PM
- Part of Theravance (THRX) will separate from partner GlaxoSmithKline (GSK) next quarter.
- Theravance Biopharma, the new firm, will retain the rights to Relvar, Breo and Anoro Ellipta drugs, with combined peak sales estimates of $3.5B.
- The company will launch with $300M in capital, one FDA-approved product Vibativ, an injectable antibiotic and three Phase 2 product candidates.
- Glaxo retains 85% rights to the three Theravance pipeline prospects.
Mar. 3, 2014, 1:06 PM
- GlaxoSmithKline (GSK -0.7%) submits its supplemental new drug application ((sNDA)) for its drug Promacta for the treatment of cytopenias (a reduction in blood cells) in patients with severe aplastic anemia (SAA), a disease characterized by the failure of the bone marrow to make enough new blood cells.
- Current approved patient groups are sufferers of chronic hepatitis C and ideopathic thrombocytopenia.
- The FDA granted Breakthrough Therapy designation to the product for SAA last month. This affords an accelerated review process similar to Fast Track designation as well as more intensive agency guidance in the drug's development.
- Top line sales for Promacta for 2013 should be ~$300M.
Mar. 3, 2014, 10:18 AM
- GSK (GSK) has called it quits on its GSK2586184 treatment for lupus - which it's developing with Belgian biotech Galapagos (GLPGF) - after a Phase 2 study failed to demonstrate a positive effect. A Phase1/2 trial for ulcerative colitis was put on hold as well, although dosing in a Phase 2 trial for the skin condition psoriasis has just been completed.
- Galapagos' relationship with Glaxo goes back seven years and included $300M in potential milestone payments. Galapagos was in line for a $34M payment for the start of the Phase 2 study.
- Glaxo's decision over lupus shows its willingness to end development that's not working - last year, the company pulled the plug on ChemoCentryx's Vercirnon, abruptly ending a $1.5B collaboration after a Phase 3 trial failed. (PR)
Feb. 28, 2014, 12:11 PM
Feb. 25, 2014, 2:14 PM
- InterMune's (ITMN +162.8%) spectacular gains after reporting positive ASCEND data (I, II) may have further to go, Baird analyst Brian Skorney believes, viewing ITMN as an ideal acquisition target for a big pharma company.
- A substantial unmet need in idiopathic pulmonary fibrosis provides a blockbuster market opportunity, Baird says, with a number of companies with the capability to sell ITMN's drug with their current salesforce, most notably GlaxoSmithKline (GSK), Gilead (GILD) and Novartis (NVS); Skorney sees a potential acquisition price into the 60s.
- Even without an acquisition, Skorney thinks ITMN should reach $44, with clinical risk is now in the rear-view mirror and potential for greater penetration and higher pricing in the U.S.
Feb. 20, 2014, 9:01 AM
- The European Medicines Agency (EMA) has recommended that the European Commission approve GlaxoSmithKline's (GSK) and Theravance's (THRX) Anoro combo treatment for chronic obstructive pulmonary disease.
- The therapy is forecast to earn revenue of over $2B a year by 2018.
- GSK and Theravance expect a decision from the EC about authorizing Anoro during Q2. The commission usually follows the advice of the EMA.
- The drug was approved in the U.S. and Canada in December. (PR)
Feb. 20, 2014, 4:33 AM
- Novartis (NVS) and Bayer (BAYRY) are among the suitors that are exploring an acquisition of Merck's (MRK) consumer-healthcare business, Reuters reports, adding that the unit could be worth $10-12B.
- Reckitt Benckiser (RBGPF) and Procter & Gamble (PG) are also among the companies to have held talks with Merck about a deal. However, GSK (GSK) is not interested.
- Novartis and Merck have considered swapping the latter's consumer-healthcare operations for Novartis' animal-health and human vaccines businesses, although such a deal is looking unlikely.
Feb. 14, 2014, 6:04 PM
- Berkshire Hathaway exited its 547K-share position in Dish Network (DISH) in Q4, as well as its 346K-share position in GlaxoSmithKline (GSK).
- Thanks to the exercising of warrants in October, Warren Buffett's company owned 10.6M shares of GE at the end of 2013, up from just 589K at the end of Q3.
- Previous: Berkshire discloses Liberty Global position
- Berkshire's Q4 13F
Feb. 5, 2014, 7:58 AM
- GlaxoSmithKline's (GSK +1.75%) Q4 core EPS of 30.1 pence is down 7%.
- Enjoys sales growth across all regions except Europe.
- Pretax profit £2.55B vs £1.73B a year earlier.
- Core pretax profit £1.94B.
- Profit attributable to shareholders £2.46B vs £848M.
- China sales of pharmaceuticals and vaccines -18% vs -61% in Q3 following bribery allegations.
- Internal rate of return on R&D investment 13% vs 12% in 2012.
- GSK projects core EPS growth of 4-8% and revenue growth of 2% at constant currencies.
- Declares quarterly dividend of 23 pence a share. (PR)
Feb. 5, 2014, 7:50 AM
- GlaxoSmithKline (GSK): Q4 EPS of £0.30 in-line.
- Revenue of £6.91B (+1.6% Y/Y)
Feb. 4, 2014, 8:28 AM
- Ten major pharmaceuticals companies are getting together with the National Institutes of Health and other organizations in a five-year partnership that will look to understand the science behind Alzheimer's, Type 2 diabetes, rheumatoid arthritis and lupus.
- In an unusual move, the normally secretive participants will share scientists, tissue, blood samples and data, with the aim being to identify targets for new drugs.
- The firms involved include Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), GlaxoSmithKline (GSK), Takeda (TKPHF) and Sanofi (SNY).
- Those that haven't joined include Amgen (AMGN), Roche (RHHBY) and AstraZeneca (AZN).
Feb. 3, 2014, 7:32 AM
- The FDA has granted "breakthrough" status to GlaxoSmithKline's (GSK) Promacta/Revolade (eltrombopag) drug for the treatment of cytopenias in patients with severe aplastic anaemia (SAA) who have had insufficient response to immunosuppressive therapy (IST).
- "SAA is a rare disorder in which the bone marrow fails to make enough new blood cells," GSK says. "Of those patients unresponsive to initial IST, approximately 40% die from infection or bleeding within five years of their diagnosis." Cytopenia is a fall in the number of blood cells. (PR)
- Meanwhile, GSK is set to announce plans to start late-stage trials on ten drugs over the next two years, The Daily Telegraph reports. The testing will include treatments in GSK's key areas of cancer and respiratory disease.
GlaxoSmithKline Plc operates as a science-led global healthcare company that researches and develops a broad range of innovative medicines and brands. It operates in three primary areas of business: Pharmaceuticals, Vaccines and Consumer Healthcare. The Pharmaceuticals business researches,... More
Industry: Drug Manufacturers - Major
Country: United Kingdom